Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
81.36
+0.04 (+0.05%)
: $81.58 +0.22 (+0.27%)
Products, Strategic Combinations

Aligos Therapeutics Expands Collaboration With Merck To Develop Oligonucleotide Therapies For NASH

Published: 01/11/2022 14:51 GMT
Merck & Co Inc (MRK) - Aligos Therapeutics Expands Collaboration With Merck to Develop Oligonucleotide Therapies for Nash.
Aligos Therapeutics Inc - Will Receive a Payment From Merck for In-license of Program Directed at a Second Undisclosed Nash Target.
Aligos Therapeutics Inc - Will Receive an Additional Payment Upon Designation of a Third Target for Collaboration.
Aligos - With Respect to Each Target in Collaboration, Will Be Eligible to Receive Up to About $460 Million in Milestones, Tiered Royalties.
Aligos - Co Primarily Responsible for Designing, Synthesizing and Evaluating Oligonucleotide Candidates and Delivering Optimized Lead Molecules.
Aligos Therapeutics Inc - Merck is Responsible for Subsequent Research, Clinical Development and Commercialization.